Real-world pharmacovigilance analysis and cross-database consistency assessment of resmetirom-related adverse events using FAERS and VigiAccess
The post-marketing safety profile and potential adverse event signals of resmetirom and cross-database concordance provides supportive, non-causal pharmacovigilance evidence, while cross-database concordance provides supportive, non-causal pharmacovigilance evidence.